Wells Fargo CEO Charlie Scharf and Pfizer CEO Albert Bourla have raised concerns about the United States’ waning competitive advantage over China, warning that inconsistent policies and underinvestment could allow the world’s second-largest economy to pull ahead.
Speaking at CNBC’s Invest in America Forum in Washington, D.C., the two executives acknowledged that the U.S. remains a leader in key industries such as finance, biotechnology, and technology. However, they cautioned that China’s strategic focus and rapid innovation are closing the gap quickly.
Both leaders agreed that artificial intelligence (AI) could play a decisive role in maintaining U.S. dominance—if deployed responsibly and supported by forward-looking economic policies.
AI: Productivity Booster, Job Reducer
Scharf said AI will inevitably reshape the American workforce. He noted that while it can dramatically improve efficiency, it may also lead to smaller workforces across industries.
“We will likely have fewer people, absolutely,” Scharf said, explaining that AI has boosted coding productivity at Wells Fargo by as much as 40%. “We haven’t reduced our head count by that percentage, but we’re doing far more than we could before.”
His remarks reflect a growing reality in corporate America, where AI is both a productivity enhancer and a disruptor. Major U.S. banks such as JPMorgan Chase and Goldman Sachs are already slowing down hiring as automation streamlines previously labor-intensive roles.
Scharf also pointed to upcoming regulatory shifts that could reshape the financial sector. He expects adjustments to capital and liquidity requirements that would affect not only large banks but also smaller community institutions.
“We do expect significant changes,” he said, suggesting that regulatory updates could eventually empower smaller banks to play a bigger role in supporting local economies.
Bourla Warns of China’s Rapid Rise in Biotech
Pfizer’s Albert Bourla expressed similar concerns about U.S. competitiveness—this time in the realm of pharmaceuticals and biotechnology. He highlighted that China has been pouring resources into R&D, modernizing regulations, and developing a national strategy for life sciences that is now bearing fruit.
“China filed more patents this year than the U.S.,” Bourla said. “That’s never happened before. Five years ago, the split was 90% to 10% in our favor. The gap is closing fast.”
Bourla urged U.S. policymakers to focus less on slowing China’s growth and more on revitalizing domestic innovation. He argued that inconsistent regulations, trade tariffs, and pricing uncertainty have hindered pharmaceutical progress at home.
“We spend more time thinking about how to slow China down than how to make ourselves better,” he said. “We need regulatory stability and clear policies. Tariffs and unpredictable pricing aren’t helping.”
Pfizer’s Drug Pricing Deal Brings Policy Stability
Bourla also discussed Pfizer’s recent agreement with the Trump administration aimed at stabilizing the pharmaceutical market. The deal provides a three-year exemption from industry-specific tariffs, in exchange for Pfizer committing to invest more in U.S. manufacturing operations.
“Tariffs and unpredictable corrections in drug pricing created major uncertainty,” Bourla said. “With this deal, we’re removing both.”
The arrangement is expected to bring greater predictability to drug pricing, Medicaid reimbursements, and distribution, while encouraging domestic production—a federal priority following pandemic-era supply chain disruptions.
AI Poised to Transform Medicine
Bourla described artificial intelligence as the next major leap in medical research, saying it will drastically accelerate the discovery of new treatments for diseases like Alzheimer’s and cancer.
“For years, we’ve struggled to find cures,” he said. “AI will make it happen.”
By analyzing vast datasets and predicting how molecules behave, AI can shorten drug development timelines from years to months. Pfizer and other pharmaceutical companies are already incorporating AI into their R&D pipelines to identify new drug candidates faster and improve clinical outcomes.
Experts believe this integration of AI could move healthcare from a reactive model to a more preventive and personalized approach, potentially saving millions of lives.
Call for a Unified National Strategy
Both Scharf and Bourla stressed that the U.S. must develop a long-term national strategy to remain competitive. They noted that while American companies lead in innovation, the absence of coherent policy frameworks often undermines their progress.
“Other nations have clear, long-term plans,” Scharf said. “We tend to operate quarter-to-quarter.”
Bourla agreed, warning that without sustained investment in science and technology, the U.S. risks losing its leadership position. “They have a national plan. We need one too,” he said.
